Faculty Information - Nobuaki Ochi

（Last updated : 2024-09-04 08:55:02）

Nobuaki Ochi
Department Kawasaki Medical School Kawasaki Medical School, Department of General Internal Medicine 4,

Position Assistant Professor

■ Journal

1.	2009/06	Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment
2.	2010/02	Obstructive jaundice at the initial presentation in small-cell lung cancer
3.	2015/01	Cisplatin-induced hyponatremia in malignancy:comparison between brand-name and generic formulation
4.	2021/12/28	Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study
5.	2021/06/12	Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404
6.	2021/04/03	Lung cancer metastasis to the pancreas mimicking autoimmune pancreatitis
7.	2021/03/29	Signifcance of PD‑L1 expression in the cytological samples of non‑small cell lung cancer patients treated with immune checkpoint inhibitors
8.	2021/02/08	Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer
9.	2020/09/01	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients
10.	2020/08/26	Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status
11.	2019/11/18	The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer
12.	2019/08	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer
13.	2018/11	Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry.
14.	2018/10	"A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403"
15.	2018/10	Acute necrotizing encephalopathy in an adult with influenza A infection.
16.	2018/08	Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: A comparison of serum Krebs von Lungen-6 and Thymus and Activation-Regulated Chemokine/CC Chemokine Ligand 17
17.	2018/08	Erythema as a Visual Surrogate Marker of Glucagonoma
18.	2018/08	Histology versus cytology: PD-L1 testing in non-small cell lung cancer
19.	2018/07	"Engagement ring" image conveys regrettable outcome for aged patients with non-small cell lung cancer.
20.	2018/02	Patients with osteosarcoma and soft tissue sarcoma might become"cancer refugee" in some Japanese regional cities
21.	2018/01	Accidental aspiration of denture cleanser tablets caused severemucosal edema in upper airway.
22.	2017/12	Ceftriaxone-associated pancreatitis captured on serial computed tomography scans.
23.	2017/12	Effects of (-)-epigallocatechin-3-gallate on EGFR- or fusion gene-driven lung cancer cells.
24.	2017/04	What can we learn from 3 phase III trials of ASCEND-4: ceritinib vs. platinum/pemetrexed with pemetrexed maintenance, PROFILE 1004: crizotinib vs. platinum/pemetrexed, and J-ALEX: alectinib vs. crizotinib?
25.	2016/11	Gynecomastia as a paraneoplastic symptom of choriocarcinoma
26.	2016/11	High uptake of Fluorodeoxy glucose along biliary stent
27.	2016/08	Cytomegalovirus Colitis in a Lung Cancer Patient.
28.	2016/06	Herpetic esophagitis following bendamustine-containing regimen
29.	2016/02	Dropped head syndrome following mantle radiation therapy
30.	2015/11	PET superscan caused by lung cancer
31.	2015/10	Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model
32.	2015/10	Progressive paraplegia caused by recurrence of mantle cell lymphoma with atypical spinal magnetic resonance imaging features
33.	2015/09	Successful palliation for an aged patient with primary pericardial mesothelioma
34.	2015/06	Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study
35.	2015/06	Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines
36.	2015/04	Non-occlusive mesenteric ischemia after splenic metastasectomy for small-cell lung cancer
37.	2014/11	Skin involvement in diffuse large B-cell lymphoma detected using positron emission tomography
38.	2014/10	Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma.
39.	2014/08	Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors
40.	2014/05	Epiphora in lung cancer patients receiving docetaxel: a case series.
41.	2014/05	Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma.
42.	2014/05	Neurogenic Pulmonary Edema After Subarachnoid Hemorrhage.
43.	2014/03	Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer
44.	2014/02	Guidelines for Long-Term Steroid Therapy In End-Of-Life Palliative Care
45.	2014/01	Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model
46.	2014/01	Fibrin sheath following pleurodesis
47.	2013/11	Successful treatment of a lung cancer patient with factor XI deficiency
48.	2013/07	Methotrexate-induced lymphoproliferative disease: Epstein-Barr virus associated lymphomatoid granulomatosis
49.	2013/05	Afatinib prolongs survival compared to gefitinib in an epidermal growth factor receptor-driven lung cancer model
50.	2013/04	Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer-A report of two cases
51.	2013/03	Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
52.	2013/03	Fatal interstitial pneumonia caused by panitumumab containing chemotherapy : a case report
53.	2013/02	Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells
54.	2013/02	Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency
55.	2013/01	Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene?
56.	2013/01	Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy
57.	2012/11	Elevated Coagulation Factor VIII Plasma Activity in a Patient with Lymphangiosarcoma
58.	2012/10	Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors
59.	2012/10	JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation
60.	2012/09	Spontaneous expectoration of tumor tissue in a patient with adenocarcinoma of the lung
61.	2012/08	Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades
62.	2012/03	Cytotoxicity of Activated Natural Killer Cells and Expression of Adhesion Molecules in Small-cell Lung Cancer
63.	2012/03	Stewart-Treves syndrome after cervical cancer
64.	2012	Asymptomatic double aortic arch with compressed oesophagus in an adult
65.	2011/12	Successful Extracorporeal Life Support for Life-threatening Hypercapnia with Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation
66.	2011/10	Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
67.	2011/10	Spontaneous regression of pulmonary pure ground-glass opacity with progression of a solid component during a 40-month follow-up
68.	2011/09	Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung.
69.	2010/02	Obstructive jaundice at the initial presentation in small-cell lung cancer.
70.	2009/11	Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
71.	2009/03	Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer.
Display 5 items
Display all(71)

■ Presentation

1.	2023/03/18	The incidence of lung cancer detection at the time of emergency room visits 救急受診時に発見された肺癌患者に関する検討（Speech，General）
2.	2018/07/20	Patients with osteosarcoma and soft tissue sarcoma tend to become cancer refugees in Japanese regional cities （Poster notice）
3.	2016/04/20	Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer （Poster notice）
4.	2015/10/08	Two Newly Discovered Mechanisms of Acquired Resistance to the Selective ALK Inhibitor Alectinib in Lung Cancer （Speech，General）
5.	2015/04/20	Both Programmed cell death protein 1 and programmed death-ligand 1 molecules can be expressed on the surface of small-cell lung cancer （Poster notice，General）
6.	2014/09/28	Acquired resistance to a new ALK inhibitor, alectinib in lung cancer （Poster notice，General）
7.	2014/04/27	Circulating TARC/CCL17 is a possible diagnostic marker for interstitial lung disease (ILD) in patients with non-small cell lung cancer (NSCLC) （Poster notice，General）
8.	2014/04/25	Inactivated ALK and Activated MET Induced Acquired Resistance to Alectinib in Lung Cancer Harboring EML4-ALK Fusion Gene in vitro （Poster notice，General）
9.	2014/04/08	ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene （Poster notice，General）
10.	2013/10/03	Mechanisms of Resistance to ALK-specific TKI CH5424802 in Lung Cancer harboring EML4-ALK （Speech，General）
11.	2013/04/08	Effects of (-)-epigallocatechin-3-gallate on EGFR or ALK driven lung cancer models （Poster notice，General）
12.	2013/04/08	PTEN deficient lung cancer cells are sensitive to the combination of olaparib with cisplatin through suppressing DNA damage signaling （Poster notice，General）
13.	2012/09/20	Afatinib prolonged survival in EGFR-driven lung cancer model compared to gefitinib （Poster notice，General）
14.	2012/04/21	Effect of AZD 1480 on lung tumor in transgenic mice carrying activating EGFR mutation （Speech，Panelist at Symposium/Workshop (Other)）
15.	2012/04/03	Afatinib prolonged survival in EGFR-driven lung cancer model compared to gefitinib （ポスター掲示，一般）
16.	2011/10/03	Effect of everolimus on lung tumorigenesis in transgenic mice carrying activating EGFR mutation （ポスター掲示，一般）
17.	2011/10/03	ERK reactivation mediated by SRC in acquired resistance to gefitinib in non-small cell lung cancer with EGFR mutation （ポスター掲示，一般）
18.	2011/06	Time trend in treatment-related deaths of patients with small cell lung cancer (SCLC) enrolled into phase III trials of systemic treatment. （抄録のみ，一般）
19.	2011/04/04	Establishment and characterization of pemetrexed-resistant lung cancer cell lines. （ポスター掲示，一般）
20.	2011/04/03	Role of ERK reactivation mediated by Src in acquired resistance to gefitinib in non-small cell lung cancer with EGFR mutation. （ポスター掲示，一般）
Display 5 items
Display all(20)